United States Patent 6,020,487: Scope, Claim Architecture, and US Landscape
What does US 6,020,487 claim cover at the product level?
US 6,020,487 is an olanzapine solid-state patent focused on specific olanzapine dihydrate polymorphs (named “Dihydrate B” and “Dihydrate E”) and on “Form II” preparation via drying. The independent claim set is structured so that composition coverage is tied to (i) dihydrate identity, (ii) crystallinity, and (iii) powder X-ray diffraction (PXRD) fingerprint ranges, plus “substantially pure” status for narrower protection.
Claim map (as provided)
| Claim |
Claim type |
Scope anchor |
Key limiting features |
| 1 |
Composition (product) |
Olanzapine dihydrate |
Selected from Dihydrate B and Dihydrate E |
| 2 |
Product dependent |
Dihydrate B |
Crystalline “Dihydrate B” + PXRD d-spacings list (all values provided) |
| 3 |
Product dependent |
Dihydrate B |
Adds relative intensity (I/I1) pattern over the same PXRD fingerprint |
| 4 |
Product dependent |
Dihydrate B |
“Substantially pure form” |
| 5 |
Product dependent |
Dihydrate E |
Crystalline “Dihydrate E” + PXRD d-spacings list |
| 6 |
Product dependent |
Dihydrate E |
Adds relative intensity (I/I1) pattern |
| 7 |
Product dependent |
Dihydrate E |
“Substantially pure form” |
| 8 |
Process |
Preparing substantially pure Form II |
Prepares olanzapine dihydrate selected from B, D, or E, then dries until Form II is prepared |
| 9 |
Process dependent |
Drying conditions |
Vacuum oven at about 40°C to about 70°C |
| 10 |
Process dependent |
Dihydrate D |
Vacuum drying claim with Dihydrate D |
| 11 |
Process dependent |
Dihydrate B |
Vacuum drying claim with Dihydrate B |
| 12 |
Process dependent |
Dihydrate E |
Vacuum drying claim with Dihydrate E |
How the claim language narrows practical coverage
1) The “selected from B and E” umbrella (Claim 1) is narrow by identity.
Claim 1 does not claim all dihydrates or all olanzapine Form II routes. It targets olanzapine dihydrate solids that are specifically “Dihydrate B” and “Dihydrate E.”
2) Claims 2–3 and 5–6 are fingerprint-constrained.
For Dihydrate B and E, the scope turns on matching the provided PXRD d-spacings and then matching relative intensities (I/I1). Even when a competitor has the right hydration state, a mismatch in PXRD fingerprint terms can fall outside these claims.
3) “Substantially pure form” (Claims 4 and 7) further limits enforceable product coverage.
Even if the competitor makes crystalline B or E, “substantially pure” can require low impurity, low admixture, or low other polymorph presence, depending on how the patent and prosecution record treated purity.
4) The process portion is “Form II by drying,” not “make dihydrate B/E.”
Claims 8–12 do not claim an unrestricted dihydrate-to-Form-II transformation. They claim a specific preparation route: start from a specified dihydrate (B, D, or E), then dry under vacuum at defined temperature to reach “Form II,” with the strongest temperature condition in Claims 9–12.
What is “Form II” doing in the scope?
“Form II” appears only in the process claims (Claims 8–12). Composition claims focus on “Dihydrate B” and “Dihydrate E,” while “Form II” acts as the endpoint for drying.
Process claim core (Claims 8–9)
- Start: olanzapine dihydrate selected from B, D, E
- Operation: drying until the Form II is prepared
- Conditions: vacuum oven about 40°C to about 70°C
Practical enforceability implication
- If a competitor avoids the specified starting dihydrate set (B/D/E), the literal process scope narrows.
- If a competitor drives the transformation to Form II using different conditions (non-vacuum drying, different temperature windows, different drying profiles), Claims 9–12 narrow quickly.
- If a competitor uses the same temperature band but uses a different starting dihydrate (for Claims 10–12 specifically), enforceability rests on whether the process still uses the claimed “selected” dihydrate species.
Which claims are the strongest for infringement risk?
In a typical solid-state dispute, the most enforceable claims are the ones that competitors are most likely to land on during manufacturing and the ones with fewer degrees of freedom. Based on the structure you provided:
Highest direct hit probability
- Claims 8–12 if manufacturing uses vacuum drying at 40°C–70°C to reach Form II from dihydrate B/D/E.
- Claims 1–3 if the product is explicitly isolated and marketed/supplied as “Dihydrate B” with PXRD fingerprint alignment.
- Claims 5–6 if the product is explicitly isolated and supplied as “Dihydrate E” with PXRD fingerprint alignment.
Most likely to be designed around
- The fingerprint-laden claims (2–3, 5–6) because a manufacturer can attempt:
- alternative crystallization conditions that shift measurable PXRD peaks and intensities, or
- produce a different polymorph or solvated form that does not match the provided PXRD pattern.
- The “substantially pure” claims (4 and 7) because impurity/polymorph admixture is often controllable at the formulation and QC stage.
How does the PXRD fingerprint structure constrain the claim boundary?
Claims 2–3 and 5–6 include long PXRD lists. This matters because:
- d-spacing lists define peak positions (even without explicit tolerances in your excerpt).
- relative intensity lists impose additional constraints beyond peak positions.
- For infringement arguments, a party typically compares measured patterns (with instrument settings and calibration) against the claim’s “typical” values.
Fingerprint length differs between B and E
- Dihydrate B lists many d-spacings (down to 2.5937 Å).
- Dihydrate E lists fewer d-spacings (down to 2.9403 Å in your excerpt).
This can shift how easily a measuring lab can compare patterns because:
- more peaks can mean more constraints,
- fewer peaks can mean a broader matching possibility.
What does the patent landscape look like in the US for olanzapine polymorphs and dihydrates?
A complete landscape requires bibliographic confirmation of US 6,020,487’s full specification details (including priority, filing family, assignee, and prosecution history) and cross-references to later re-issues, continuations, and Hatch-Waxman blocking patents. Your input provides the claim set but not the patent’s publication metadata or family mapping.
Because of that, a full US landscape map (which patents cover which exact olanzapine forms, which are composition vs process, and which are still active) cannot be produced accurately from the claim excerpt alone.
Actionable scope conclusions for business and R&D
Even without a full family tree, US 6,020,487 can be operationalized for decision-making using the claim mechanics you provided.
Manufacturing process design implications
A facility producing olanzapine solids should treat the patent as a constraint on:
- which dihydrate seed is used to form “Form II”
- whether drying is done in a vacuum oven in the 40°C–70°C window
- how product identity is QC’d for “Dihydrate B” or “Dihydrate E” in isolated form
Product strategy implications
If a manufacturer supplies “Dihydrate B” or “Dihydrate E” as an intermediate or drug substance, infringement risk concentrates on:
- meeting the crystalline identity requirements, and
- matching the claim’s PXRD fingerprint values for both d-spacings and relative intensities, and
- achieving “substantially pure” status.
Commercial leverage points
For licensing or freedom-to-operate:
- Process claims (8–12) are commonly narrower than composition claims because they require both starting material identity and drying conditions.
- Composition claims (2–7) are commonly broader than process claims in one dimension (any making) but narrower in another (fingerprint match).
Key Takeaways
- US 6,020,487’s product scope is limited to olanzapine dihydrate Dihydrate B and Dihydrate E, with crystalline identity and PXRD fingerprint constraints (d-spacings and relative intensity patterns).
- The narrower “substantially pure” claims (4 and 7) add an additional limitation that can be used as a design-around through controlled impurity/polymorph content.
- The process scope targets preparation of Form II by drying an olanzapine dihydrate selected from B, D, or E, with the key condition of vacuum oven drying at about 40°C to about 70°C (Claims 9–12).
- Enforcement risk will cluster around (i) whether manufacturing uses the claimed dihydrate starting materials and (ii) whether vacuum drying and temperature windows match, plus (iii) whether isolated solids match the specific PXRD fingerprints.
FAQs
1) Does US 6,020,487 claim all olanzapine dihydrates?
No. Claim 1 limits dihydrates to those “selected from Dihydrate B and Dihydrate E,” and dependent composition claims then lock in PXRD fingerprints for each.
2) Are the PXRD values mandatory for infringement?
For the fingerprint-dependent claims (2–3 for Dihydrate B and 5–6 for Dihydrate E), infringement turns on matching the claimed “typical” PXRD d-spacings and relative intensity patterns.
3) What drying conditions matter most in the process claims?
Claim 9 fixes a “vacuum oven” condition and a temperature band of about 40°C to about 70°C.
4) Do the process claims require “Form II” as the endpoint?
Yes. Claim 8 requires drying “until the Form II is prepared.”
5) Can a manufacturer avoid risk by using a different drying method?
Risk decreases if the process does not use the claimed vacuum drying conditions and/or does not start from the claimed dihydrate species that the process claims require (B/D/E).
References
- US Patent 6,020,487 (claims as provided by user).
